bupropion has been researched along with Neoplasms in 18 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions." | 9.41 | Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023) |
| "For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life." | 9.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| "This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life." | 9.12 | An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006) |
| "This is the first report that shows bupropion SR can reduce fatigue in cancer patients." | 7.72 | Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004) |
| "Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6." | 6.94 | Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020) |
| "Nicotine dependence is a significant addiction with many health consequences." | 6.47 | Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. ( Grief, SN, 2011) |
| "This study aimed to systematically assess the evidence on the efficacy and safety of bupropion in the treatment of fatigue in people with cancer and non-cancer conditions." | 5.41 | Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review. ( Correa-Morales, JE; Cuellar-Valencia, L; Giraldo-Moreno, S; Iriarte-Aristizábal, MF; Mantilla-Manosalva, N; Quintero-Muñoz, E; Rodríguez-Campos, LF, 2023) |
| "For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life." | 5.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| "This preliminary study investigated whether bupropion sustained release (SR) improved symptomatic fatigue, depression and quality of life in cancer patients and caregiver quality of life." | 5.12 | An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. ( Forsyth, P; Moss, EL; Pelletier, G; Simpson, JS, 2006) |
| " This study evaluated the feasibility, safety, and effect on cessation of varenicline for smoking cessation in patients with cancer." | 3.85 | The use of varenicline to treat nicotine dependence among patients with cancer. ( Blazekovic, S; Brubaker, TR; Hitsman, B; Hole, A; Kalhan, R; Langer, C; Leone, F; Patel, J; Price, S; Schnoll, R; Veluz-Wilkins, A; Wileyto, EP, 2017) |
| "This is the first report that shows bupropion SR can reduce fatigue in cancer patients." | 3.72 | Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004) |
| " We also analyzed the adverse event profile differences between the medications." | 3.11 | Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. ( Beneventi, D; Blalock, JA; Chaftari, P; Cinciripini, PM; Cui, Y; Gonzalez, R; Karam-Hage, M; Kypriotakis, G; Robinson, JD; Tayar, J, 2022) |
| "Sonidegib dosed orally at 800 mg QD (higher than the Food and Drug Administration-approved dose) did not impact the PK or pharmacodynamics of warfarin (CYP2C9 probe substrate) or the PK of bupropion (CYP2B6 probe substrate)." | 3.01 | The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. ( Amaravadi, RK; Britten, CD; Chung, V; Gutierrez, M; Lee, JJ; Lewis, LD; LoRusso, P; Ness, DB; O'Rourke, MA; Olszanski, AJ; Perez, R; Pooler, DB; Ravichandran, S; Sarantopoulos, J; Shapiro, GI; Squittieri, N; Vaishampayan, U, 2021) |
| "Bupropion was administered 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6." | 2.94 | Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. ( Azimi, S; Borhani, S; Hendouei, N; Janbabai, G; Saghafi, F; Salehifar, E; Zaboli, E, 2020) |
| "Among smokers recently diagnosed with cancer in 2 National Cancer Institute-designated Comprehensive Cancer Centers, sustained counseling and provision of free cessation medication compared with 4-week counseling and medication advice resulted in higher 6-month biochemically confirmed quit rates." | 2.94 | Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial. ( Borderud, S; Cooley, ME; de León-Sanchez, S; Friedman, ER; Gonzalez, I; Holland, S; Hyland, KA; Irwin, KE; Kwon, D; Levy, DE; Malloy, L; Miller-Sobel, J; Muzikansky, A; O'Brien, M; Ostroff, JS; Park, ER; Partridge, AH; Perez, GK; Peterson, L; Pirl, WF; Ponzani, C; Rabin, J; Regan, S; Rigotti, NA; Sprunck, K; Temel, JS; Whitlock, CW, 2020) |
| "Many cancer patients continue to smoke postdiagnosis, which is associated with poorer clinical outcomes." | 2.76 | Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program. ( Langer, C; Leone, F; Martinez, E; Miyamoto, C; Schnoll, RA, 2011) |
| "Nicotine dependence is a significant addiction with many health consequences." | 2.47 | Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy. ( Grief, SN, 2011) |
| "Smokers with cancer do not smoke by life-style choice but because they are highly addicted and are suffering from a chronic relapsing disease: tobacco dependence, which justifies intensive medical management." | 1.38 | [Methods and results of smoking cessation in cancer smoker's]. ( Dautzenberg, B, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Robinson, JD | 1 |
| Karam-Hage, M | 1 |
| Kypriotakis, G | 1 |
| Beneventi, D | 1 |
| Blalock, JA | 1 |
| Cui, Y | 1 |
| Gonzalez, R | 1 |
| Tayar, J | 1 |
| Chaftari, P | 1 |
| Cinciripini, PM | 1 |
| Correa-Morales, JE | 1 |
| Cuellar-Valencia, L | 1 |
| Mantilla-Manosalva, N | 1 |
| Quintero-Muñoz, E | 1 |
| Iriarte-Aristizábal, MF | 1 |
| Giraldo-Moreno, S | 1 |
| Rodríguez-Campos, LF | 1 |
| Salehifar, E | 1 |
| Azimi, S | 1 |
| Janbabai, G | 1 |
| Zaboli, E | 1 |
| Hendouei, N | 1 |
| Saghafi, F | 1 |
| Borhani, S | 1 |
| Pooler, DB | 1 |
| Ness, DB | 1 |
| Sarantopoulos, J | 1 |
| Squittieri, N | 1 |
| Ravichandran, S | 1 |
| Britten, CD | 1 |
| Amaravadi, RK | 1 |
| Vaishampayan, U | 1 |
| LoRusso, P | 1 |
| Shapiro, GI | 1 |
| Olszanski, AJ | 1 |
| Perez, R | 1 |
| Gutierrez, M | 1 |
| O'Rourke, MA | 1 |
| Chung, V | 1 |
| Lee, JJ | 1 |
| Lewis, LD | 1 |
| Park, ER | 1 |
| Perez, GK | 1 |
| Regan, S | 1 |
| Muzikansky, A | 1 |
| Levy, DE | 1 |
| Temel, JS | 1 |
| Rigotti, NA | 1 |
| Pirl, WF | 1 |
| Irwin, KE | 1 |
| Partridge, AH | 1 |
| Cooley, ME | 1 |
| Friedman, ER | 1 |
| Rabin, J | 1 |
| Ponzani, C | 1 |
| Hyland, KA | 1 |
| Holland, S | 1 |
| Borderud, S | 1 |
| Sprunck, K | 1 |
| Kwon, D | 1 |
| Peterson, L | 1 |
| Miller-Sobel, J | 1 |
| Gonzalez, I | 1 |
| Whitlock, CW | 1 |
| Malloy, L | 1 |
| de León-Sanchez, S | 1 |
| O'Brien, M | 1 |
| Ostroff, JS | 1 |
| Ashrafi, F | 1 |
| Mousavi, S | 1 |
| Karimi, M | 1 |
| Lin, CY | 1 |
| Lee, CH | 1 |
| Chuang, YH | 1 |
| Lee, JY | 1 |
| Chiu, YY | 1 |
| Wu Lee, YH | 1 |
| Jong, YJ | 1 |
| Hwang, JK | 1 |
| Huang, SH | 1 |
| Chen, LC | 1 |
| Wu, CH | 1 |
| Tu, SH | 1 |
| Ho, YS | 1 |
| Yang, JM | 1 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 1 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Boušová, I | 1 |
| Skálová, L | 1 |
| Souček, P | 1 |
| Matoušková, P | 1 |
| Price, S | 1 |
| Hitsman, B | 1 |
| Veluz-Wilkins, A | 1 |
| Blazekovic, S | 1 |
| Brubaker, TR | 1 |
| Leone, F | 3 |
| Hole, A | 1 |
| Wileyto, EP | 2 |
| Langer, C | 3 |
| Kalhan, R | 1 |
| Patel, J | 1 |
| Schnoll, R | 1 |
| Schnoll, RA | 2 |
| Martinez, E | 2 |
| Tatum, KL | 1 |
| Weber, DM | 1 |
| Kuzla, N | 1 |
| Glass, M | 1 |
| Ridge, JA | 1 |
| Miyamoto, C | 2 |
| Grief, SN | 1 |
| Dautzenberg, B | 1 |
| Cullum, JL | 1 |
| Wojciechowski, AE | 1 |
| Pelletier, G | 2 |
| Simpson, JS | 2 |
| Moss, EL | 1 |
| Forsyth, P | 1 |
| Tucker, WE | 1 |
| Vainio, H | 1 |
| Weiderpass, E | 1 |
| Kleihues, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors[NCT01769768] | Phase 1 | 114 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial[NCT01871506] | 303 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The cost of the standard of care treatment and the cost of the intensive treatment. (NCT01871506)
Timeframe: 6 months
| Intervention | dollars (Mean) |
|---|---|
| Standard Treatment (ST) | 638 |
| Intensive Treatment | 1144 |
Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (<15 ng/ml76, 82) or <10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT (NCT01871506)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Treatment (ST) | 28 |
| Intensive Treatment (IT) | 46 |
Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (<15 ng/ml76, 82) or <10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT (NCT01871506)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Treatment (ST) | 29 |
| Intensive Treatment (IT) | 51 |
Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 & 6 months (NCT01871506)
Timeframe: 3 months to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Treatment | 26 |
| Intensive Treatment) | 43 |
Number of Participants with Self-reported smoking abstinence of at least 7 days (NCT01871506)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Treatment (ST) | 42 |
| Intensive Treatment (IT) | 54 |
Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 & 6 months (NCT01871506)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Treatment (ST) | 17 |
| Intensive Treatment (IT) | 35 |
The number of intervention participants who took 1-2 4-week refills of smoking cessation medication (NCT01871506)
Timeframe: Treatment Initiation to 6 Month Follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Treatment (IT) | 87 |
The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling (NCT01871506)
Timeframe: Treatment Initiation to 6 Month Follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Treatment (IT) | 99 |
The number of intervention participants who used smoking cessation counseling during the study (Y/N) (NCT01871506)
Timeframe: Treatment Initiation to 6 Month Follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Treatment (IT) | 153 |
The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions. (NCT01871506)
Timeframe: Treatment Initiation to 6 month follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Treatment (IT) | 122 |
4 reviews available for bupropion and Neoplasms
| Article | Year |
|---|---|
Cancer and Non-cancer Fatigue Treated With Bupropion: A Systematic Review.
Topics: Adult; Bupropion; Fatigue; Humans; Neoplasms | 2023 |
The modulation of carbonyl reductase 1 by polyphenols.
Topics: Alcohol Oxidoreductases; Animals; Bupropion; Butanones; Butyrophenones; Daunorubicin; Doxorubicin; G | 2015 |
Nicotine dependence: health consequences, smoking cessation therapies, and pharmacotherapy.
Topics: Administration, Cutaneous; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Heart Diseases; Huma | 2011 |
Smoking cessation in cancer prevention.
Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropion; Humans; Neoplasms; Risk Facto | 2001 |
7 trials available for bupropion and Neoplasms
| Article | Year |
|---|---|
Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center.
Topics: Bupropion; Humans; Neoplasms; Smoking; Smoking Cessation; Tobacco Smoking; Tobacco Use Cessation Dev | 2022 |
Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial.
Topics: Adult; Aged; Bupropion; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2020 |
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Topics: Administration, Oral; Area Under Curve; Biphenyl Compounds; Bupropion; Drug Interactions; Humans; Ne | 2021 |
Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial.
Topics: Aged; Bupropion; Cotinine; Counseling; Decision Support Techniques; Female; Humans; Male; Middle Age | 2020 |
A bupropion smoking cessation clinical trial for cancer patients.
Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Depression; Depressi | 2010 |
Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program.
Topics: Behavior Therapy; Bupropion; Female; Humans; Male; Middle Aged; Neoplasms; Nicotine; Placebos; Progn | 2011 |
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Delayed-Action Preparati | 2006 |
7 other studies available for bupropion and Neoplasms
| Article | Year |
|---|---|
Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action | 2018 |
Membrane protein-regulated networks across human cancers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bupropion; Cell Line, Tumor; Datasets as Topic; F | 2019 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
The use of varenicline to treat nicotine dependence among patients with cancer.
Topics: Adult; Benzazepines; Bupropion; Counseling; Feasibility Studies; Female; Humans; Male; Middle Aged; | 2017 |
[Methods and results of smoking cessation in cancer smoker's].
Topics: Benzazepines; Bupropion; Humans; Neoplasms; Nicotinic Agonists; Quinoxalines; Secondary Prevention; | 2012 |
Bupropion sustained release treatment reduces fatigue in cancer patients.
Topics: Adjustment Disorders; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiet | 2004 |
Preclinical toxicology of bupropion: an overview.
Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents; Bupropion; Central Nervous System; Chem | 1983 |